Advion Inc.

advion.com

Advion, Inc. was founded in 1993 based on the novel techniques developed within the Cornell University laboratory of Dr. Jack Henion, a leading researcher in the field of Liquid Chromatography/Mass Spectrometry (LC/MS). Pioneers within the industry, Advion offers a variety of fit-for-purpose systems and consumables for life science research. With sales and support offices in North America and Europe and a large network of distributors, Advion is a global company with customers in all of the top pharmaceutical companies, government life science research agencies and universities. Advion continues to expand its diverse portfolio of innovative microfluidic and mass spec – based products for the life science industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

SARTORIUS STEDIM BIOTECH ACQUIRES U.S.-BASED PURIFICATION EXPERT WATERSEP BIOSEPARATIONS LLC

Sartorius Stedim Biotech | December 10, 2020

news image

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million ...

Read More

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

news image

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

news image

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

news image

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More
news image

Industry Outlook

SARTORIUS STEDIM BIOTECH ACQUIRES U.S.-BASED PURIFICATION EXPERT WATERSEP BIOSEPARATIONS LLC

Sartorius Stedim Biotech | December 10, 2020

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million ...

Read More
news image

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ROCKET PHARMACEUTICALS' RP-A501 RECEIVES FDA RMAT DESIGNATION

Rocket Pharmaceuticals, Inc | February 09, 2023

On February 7, 2023, Rocket Pharmaceuticals Inc., a renowned late-stage biotech firm advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet needs, announced that FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the company's investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease, a life-threatening genetic cardiac disease with no disease-altering therapies available. RMAT s...

Read More
news image

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us